0001179110-21-000561.txt : 20210112 0001179110-21-000561.hdr.sgml : 20210112 20210112190807 ACCESSION NUMBER: 0001179110-21-000561 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210108 FILED AS OF DATE: 20210112 DATE AS OF CHANGE: 20210112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lim Bryant David CENTRAL INDEX KEY: 0001752888 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 21524577 MAIL ADDRESS: STREET 1: C/O IDERA PHARMACEUTICALS, INC. STREET 2: 505 EAGLEVIEW BLVD., SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 4843481600 MAIL ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 4 1 edgar.xml FORM 4 - X0306 4 2021-01-08 0 0000861838 IDERA PHARMACEUTICALS, INC. IDRA 0001752888 Lim Bryant David C/O IDERA PHARMACEUTICALS, INC. 505 EAGLEVIEW BLVD., SUITE 212 EXTON PA 19341 0 1 0 0 SVP and General Counsel Common Stock 2021-01-12 4 S 0 1711 4.2091 D 38064 D Stock Option (Right to Buy) 4.28 2021-01-08 4 A 0 51000 0 A 2031-01-08 Common Stock 51000 51000 D Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.1901 to $4.239 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Of the reported securities beneficially owned, 24,050 shares are represented by unvested RSUs. The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. /s/ Bryant D. Lim 2021-01-12